Alzheimer’s Patients Currently Being Enrolled For Phase III Eli Lilly Study

Eli Lilly and Co has started a Phase III Clinical Trial of LY450139, an investigational gamma secretase inhibitor for the treatment of patients with mild/moderate Alzheimer’s disease. The trial aims to see whether it can slow the progression associated with Alzheimer’s by inhibiting gamma-secretase. Gamma-secretase is an enzyme that can create amyloid beta - a sticky protein.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on April 2nd, 2008